Enfermidades Infecciosas
Hospital General Universitario de Elche
Elche, EspañaPublicacións en colaboración con investigadores/as de Hospital General Universitario de Elche (16)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
Incidence of Anal Cancer and Related Risk Factors in HIV-Infected Patients Enrolled in the National Prospective Spanish Cohort CoRIS
Diseases of the Colon and Rectum, Vol. 66, Núm. 12, pp. E1186-E1194
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus as a chronic disease: Evaluation and management of nonacquired immune deficiency syndrome-defining conditions
Open Forum Infectious Diseases, Vol. 3, Núm. 2
-
Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: Estimates and risk factors
AIDS, Vol. 30, Núm. 1, pp. 37-44
2015
-
Cardiovascular risk factors and lifetime risk estimation in hiv-infected patients under antiretroviral treatment in Spain
HIV Clinical Trials, Vol. 16, Núm. 2, pp. 57-65
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2014
-
Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597
-
Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH
Nefrologia, Vol. 34, Núm. 6, pp. 768-788
2011
-
Clinical utility of maraviroc
Clinical Drug Investigation, Vol. 31, Núm. 8, pp. 527-542
2009
-
Disorders of body fat distribution in HIV-1-infected patients
AIDS Reviews, Vol. 11, Núm. 3, pp. 126-134
-
The Spanish HIV BioBank: A model of cooperative HIV research
Retrovirology, Vol. 6